Kristen Magas, Anderson Wilder, Obaid Alsuwaidi, and Tiffany Snyder (from left to right) will live in a Mars simulation for 45 days. Photos courtesy of NASA

Four individuals have been selected to go to Mars. Well, sort of.

Obaid Alsuwaidi, Kristen Magas, Tiffany Snyder, and Anderson Wilder were picked by NASA to live for 45 days in a 650-square-foot Mars simulation located at Johnson Space Center in Houston. The participants will enter the Human Exploration Research Analog, or HERA, on Friday, November 1, and will live and work like astronauts until Monday, December 16.

Jordan Hundley and Robert Wilson also were named as alternate crew members.

"Scientists use HERA studies to examine how crew members adapt to isolation, confinement, and remote conditions before NASA sends astronauts on deep space missions to the Moon, Mars, and beyond," reads NASA's announcement. "The studies provide data about human health and performance in an enclosed environment over time with crews facing different challenges and tasks."

In the experiment, the participants will complete research and operational duties, including raising shrimp, farming, and completing virtual reality-simulated walks on Mars. In addition to these tasks, the crew will experience communication delays similar to ones astronauts will face on future missions to Mars and beyond, which could be as long as 20 minutes each way.

Through NASA’s Human Research Program, the crew members will participate in 18 human health studies focused on physiological, behavioral, and psychological health during the mission.

Here's a little more about each of the crew members:

  • As captain engineer for the United Arab Emirates’ Ministry of Defense, Obaid Alsuwaidi, provides guidance in civil and marine engineering and addresses challenges facing the organization.
  • Kristen Magas, an educator and engineer currently teaching at Tri-County Regional Vocational Technical High School in Franklin, Massachusetts, mentors students involved in a NASA design and prototyping program.
  • With more than 20 years of information technology and cybersecurity experience, Tiffany Snyder is a supervisor for the Cybersecurity Mission Integration Office at NASA, helping to ensure agency missions are shielded against cybersecurity threats.
  • Currently researching team resiliency and human-machine interactions, Anderson Wilder is a Florida Institute of Technology graduate student working on his doctorate in Psychology and previously served as an executive officer and engineer for an analog mission at the Mars Desert Research Station in Utah.
  • Jordan Hundley (alternate) is a senior consultant at a professional services firm, offering federal agencies technical and programmatic support.
  • Robert Wilson (alternate) is a senior researcher and project manager at the Johns Hopkins University Applied Physics Laboratory in Laurel, Maryland.
Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Nominations are now open for the 2025 Houston Innovation Awards

Calling All Innovators

Calling all Houston innovators: The Houston Innovation Awards return this fall to celebrate the best and brightest in the Houston innovation ecosystem right now.

Presented by InnovationMap, the fifth annual Houston Innovation Awards will take place November 5 at TMC Helix Park.

The awards program will honor the top startups and innovators in Houston across 10 categories, and we're asking you to nominate the most deserving Houston innovators and innovative companies today.

This year's categories are:

  • Minority-founded Business, honoring an innovative startup founded or co-founded by BIPOC or LGBTQ+ representation.
  • Female-founded Business, honoring an innovative startup founded or co-founded by a woman.
  • Energy Transition Business, honoring an innovative startup providing a solution within renewables, climatetech, clean energy, alternative materials, circular economy, and beyond.
  • Health Tech Business, honoring an innovative startup within the health and medical technology sectors.
  • Deep Tech Business, honoring an innovative startup providing technology solutions based on substantial scientific or engineering challenges, including those in the AI, robotics, and space sectors.
  • Startup of the Year (People's Choice), honoring a startup celebrating a recent milestone or success. The winner will be selected by the community via an interactive voting experience.
  • Scaleup of the Year, honoring an innovative later-stage startup that's recently reached a significant milestone in company growth.
  • Incubator/Accelerator of the Year, honoring a local incubator or accelerator that is championing and fueling the growth of Houston startups.
  • Mentor of the Year, honoring an individual who dedicates their time and expertise to guide and support budding entrepreneurs.
  • Trailblazer, honoring an innovator who's made a lasting impact on the Houston innovation community.

Nominations may be made on behalf of yourself, your organization, and other leaders in the local innovation scene. The nomination period closes on August 31, so don't delay — nominate today at this link, or fill out the embedded form below.

Our panel of esteemed judges will review the nominations, and determine the finalists and winners. Finalists will be unveiled on September 30, and the 2025 Houston Innovation Awards winners will be announced live at our event on November 5.

Tickets will go on sale this fall. Stay tuned for that announcement, as well as more fanfare leading up to the 2025 Houston Innovation Awards.

Nominate now:

Interested in Innovation Awards sponsorship opportunities? Please contact sales@innovationmap.com.

MD Anderson launches $10M collaboration to advance personalized cancer treatment tech

fighting cancer

The University of Texas MD Anderson Cancer Center and Japan’s TOPPAN Holdings Inc. have announced a strategic collaboration to co-develop TOPPAN Holdings’ 3D cell culture, or organoid, technology known as invivoid.

The technology will be used as a tool for personalized cancer treatments and drug screening efforts, according to a release from MD Anderson. TOPPAN has committed $10 million over five years to advance the joint research activities.

“The strategic alliance with MD Anderson paves a promising path toward personalized cancer medicine," Hiroshi Asada, head of the Business Innovation Center at TOPPAN Holdings, said in a news release.

Invivoid is capable of establishing organoid models directly from patient biopsies or other tissues in a way that is faster and more efficient. Researchers may be able to test a variety of potential treatments in the laboratory to understand which approach may work best for the patient, if validated clinically.

“Organoids allow us to model the three-dimensional complexity of human cancers in the lab, thus allowing us to engineer a powerful translational engine—one that could not only predict how patients will respond to therapy before treatment begins but also could help to reimagine how we discover and validate next-generation therapies," Dr. Donna Hansel, division head of pathology and laboratory medicine at MD Anderson, added in the news release. “Through this collaboration, we hope to make meaningful progress in modeling cancer biology for therapeutic innovation.”

The collaboration will build upon preclinical research previously conducted by MD Anderson and TOPPAN. The organizations will work collaboratively to obtain College of American Pathologists (CAP) and Clinical Laboratory Improvement Amendments (CLIA) certifications for the technology, which demonstrate a commitment to high-quality patient care. Once the certifications are obtained, they plan to conduct observational clinical studies and then prospective clinical studies.

“We believe our proprietary invivoid 3D cell culture technology, by enabling the rapid establishment of organoid models directly from patient biopsies, has strong potential to help identify more effective treatment options and reduce the likelihood of unnecessary therapies,” Asada added in the release. “Through collaboration on CAP/CLIA certification and clinical validation, we aim to bring this innovation closer to real-world patient care and contribute meaningfully to the advancement of cancer medicine."